Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Cannabidiol reduces seizure rate in rare form of epilepsy

Study finds that use of cannabidiol reduces frequency of drop seizures in people with Lennox-Gastaut syndrome.

Cannabidiol (Epidiolex; GW Pharma) reduces the risk of drop seizures in people with Lennox-Gastaut syndrome, a rare, severe form of epilepsy, according to the results of a recent study (17 May 2018)[1].

The trial randomly assigned 225 patients who were experiencing at least two drop seizures per week to cannabidiol 10mg/kg or 20mg/kg, or placebo, in addition to their usual antiseizure medication.

During the 28-day treatment period, the median number of drop seizures declined by 41.9% in patients assigned to cannabidiol 20mg/kg and by 37.2% in those assigned to cannabidiol 10mg/kg, compared with 17.2% in the placebo group, the team reported in the New England Journal of Medicine (17 May 2018).

Drop seizures, in which patients experience a sudden loss of muscle tone, are a hallmark of Lennox-Gastaut syndrome and frequently continue despite pharmaceutical treatment.

“This landmark study provides data and evidence that Epidiolex can be an effective and safe treatment for seizures seen in patients with Lennox-Gastaut syndrome, a very difficult to control epilepsy syndrome,” concludes Anup Patel, lead study author from the Nationwide Children’s Hospital in Columbus, Ohio.

The US Food and Drug Administration has approved Epidiolex for use in the United States, but it is not yet licensed in the UK.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205058

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Pharmacy OSCEs

    Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Cannabidiol, bottled

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.